Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
PHASE1CompletedINTERVENTIONAL
Enrollment
33
Participants
Timeline
Start Date
December 11, 2013
Primary Completion Date
June 6, 2014
Study Completion Date
June 6, 2014
Conditions
Renal InsufficiencyRenal Impairment
Interventions
DRUG
sugammadex
sugammadex 4 mg/kg IV bolus
Trial Locations (1)
33014
Investigational Site 001, Hialeah
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02011490 - Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105) | Biotech Hunter | Biotech Hunter